Contribution of clinical trials to gross domestic product in HungaryReport as inadecuate




Contribution of clinical trials to gross domestic product in Hungary - Download this document for free, or read online. Document in PDF available to download.

Croatian medical journal, Vol.55 No.5 October 2014. -

Aim To determine the contribution of clinical trials to the

gross domestic product GDP in Hungary.

Methods An anonymous survey of pharmaceutical companies

and clinical research organizations CROs was conducted

to estimate their clinical trial-related employment

and revenues. Clinical trial documents at the National Institute

of Pharmacy NIP were analyzed to estimate trial-related

revenues at health care institutions and the value of

investigational medical products IMPs based on avoided

drug costs. Financial benefits were calculated as 2010 US $

purchasing power parity PPP values.

Results Clinical trials increased the revenue of Hungarian

health care providers by US $165.6 million. The value

of IMPs was US $67.0 million. Clinical trial operation and

management activities generated 900 jobs and US $166.9

million in revenue among CROs and pharmaceutical companies.

Conclusions The contribution of clinical trials to the Hungarian

GDP in 2010 amounted to 0.2%. Participation in international

clinical trials may result in health, financial, and

intangible benefits that contribute to the sustainability of

health care systems, especially in countries with severe resource

constraints. Although a conservative approach was

employed to estimate the economic benefits of clinical trials,

further research is necessary to improve the generalizability

of our findings.



Author: Zoltán Kaló - ; Eötvös Loránd University ELTE, Department of Health Policy and Health Economics, Budapest, Hungary János An

Source: http://hrcak.srce.hr/



DOWNLOAD PDF




Related documents